Estrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer
- 15 March 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (6) , 2029-2034
- https://doi.org/10.1158/1078-0432.ccr-03-1061
Abstract
Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied. Experimental Design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum. Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P < 0.001). Only 3.9% of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (Pintercept = 0.0002, Pslope = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (Pslope = 0.98). Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.Keywords
This publication has 21 references indexed in Scilit:
- Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation CarriersJournal of Clinical Oncology, 2004
- Estrogen Receptor α Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid InfiltratesThe American Journal of Pathology, 2003
- Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinomaCancer, 2003
- Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2JAMA, 2001
- Gene-Expression Profiles in Hereditary Breast CancerNew England Journal of Medicine, 2001
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 2000
- Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriersThe Lancet, 1998
- Estrogen receptor-negative epithelial cells in mouse mammary gland development and growthDifferentiation, 1998
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 1992
- Estrogen and Progesterone Receptor Determinations in Breast Cancer—Technology, Biology and Clinical SignificanceActa Oncologica, 1988